One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Commercial determinants of cancer
doi : 10.1016/S1470-2045(23)00640-X
Volume 25, Issue 1, January 2024, Page 1
Evolution of front-line immunotherapy for metastatic urothelial cancer
*Arlene O Siefker-Radtke, Monica Desai
doi : 10.1016/S1470-2045(23)00633-2
Volume 25, Issue 1, January 2024, Pages 2-3
Adjuvant or neoadjuvant treatment with immune checkpoint inhibitors: re-assessing the risk–benefit ratio
Julie Delyon, Olivier Michielin
doi : 10.1016/S1470-2045(23)00575-2
Volume 25, Issue 1, January 2024, Pages 3-5
Is there finally a place for neoadjuvant treatment in locally advanced cervical cancer?
Patricia Pautier
doi : 10.1016/S1470-2045(23)00576-4
Volume 25, Issue 1, January 2024, Pages 5-6
Utilising cancer registry data to monitor cancer burden
*Karri Sepp?, Janne Pitk?niemi
doi : 10.1016/S1470-2045(23)00596-X
Volume 25, Issue 1, January 2024, Pages 6-7
Serum hormone concentrations and individualisation of breast cancer prevention
Saranya Chumsri
doi : 10.1016/S1470-2045(23)00635-6
Volume 25, Issue 1, January 2024, Pages 8-9
Liver MRI in patients scheduled for local therapy of colorectal liver metastases
Federica Vernuccio
doi : 10.1016/S1470-2045(23)00614-9
Volume 25, Issue 1, January 2024, Pages 9-10
When less is more—reducing complexity in cancer trials
Timil H Patel, Donna R Rivera, Harpreet Singh, *Paul G Kluetz
doi : 10.1016/S1470-2045(23)00627-7
Volume 25, Issue 1, January 2024, Pages 10-12
Mitotane and the myth of 14 mg/L
Matthew I Ehrlich, Brian W Labadie, Susan E Bates, *Tito Fojo
doi : 10.1016/S1470-2045(23)00537-5
Volume 25, Issue 1, January 2024, Pages 12-15
Universal testing of cutaneous sebaceous carcinoma: a missed opportunity in Lynch syndrome detection
Neil Rajan, Sam Cook, Katie Best, †Lynch Syndrome UK Sebaceous Carcinoma group, Kevin Monahan
doi : 10.1016/S1470-2045(23)00595-8
Volume 25, Issue 1, January 2024, Pages e1-e2
Correction to Lancet Oncol 2020; 21: 671–84
doi : 10.1016/S1470-2045(23)00642-3
Volume 25, Issue 1, January 2024, Page e3
Correction to Lancet Oncol 2024; 25: e6–17
doi : 10.1016/S1470-2045(23)00617-4
Volume 25, Issue 1, January 2024, Page e3
Carcinogenicity of perfluorooctanoic acid and perfluorooctanesulfonic acid
Aline de Conti, Caterina Facchin, Federica Madia, Heidi Mattock, Mira Merdas, Elisa Pasqual, Eero Suonio, Susana Viegas, Ljubica Zupunski, Roland Wedekind*, Mary K Schubauer-Berigan*
doi : 10.1016/S1470-2045(23)00622-8
Volume 25, Issue 1, January 2024, Pages 16-17
Australia's new cancer nursing and navigation plan
Manjulika Das
doi : 10.1016/S1470-2045(23)00623-X
Volume 25, Issue 1, January 2024, Page 18
New Zealand backtracks on antismoking laws
Tony Kirby
doi : 10.1016/S1470-2045(23)00624-1
Volume 25, Issue 1, January 2024, Page 19
Agreement to reduce industrial emissions in Europe
Manjulika Das
doi : 10.1016/S1470-2045(23)00630-7
Volume 25, Issue 1, January 2024, Page 20
FDA investigates risk of secondary lymphomas after CAR-T immunotherapy
Bryant Furlow
doi : 10.1016/S1470-2045(23)00631-9
Volume 25, Issue 1, January 2024, Page 21
New French national tobacco control programme
Barbara Casassus
doi : 10.1016/S1470-2045(23)00632-0
Volume 25, Issue 1, January 2024, Page 22
Measures to improve cancer situation in Cyprus
Manjulika Das
doi : 10.1016/S1470-2045(23)00644-7
Volume 25, Issue 1, January 2024, Page e4
Morphine manifesto seeks to boost access to oral morphine
Dinesh C Sharma
doi : 10.1016/S1470-2045(23)00645-9
Volume 25, Issue 1, January 2024, Page e5
Shortages of essential cancer medicines: who is responsible and what are the possible solutions?
*Kristina Jenei, Mark P Lythgoe, Kerstin N Vokinger
doi : 10.1016/S1470-2045(23)00470-9
Volume 25, Issue 1, January 2024, Pages 23-26
Dignity and inequality at the end of life
Robert Stirrups
doi : 10.1016/S1470-2045(23)00618-6
Volume 25, Issue 1, January 2024, Pages 26-28
Atezolizumab plus chemotherapy versus placebo plus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis results from a randomised, controlled, phase 3 study
Enrique Grande, José ? Arranz, Maria De Santis, Aristotelis Bamias, Eiji Kikuchi, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Fabio A Schutz, Javier Puente, Jian-Ri Li, Peter H O’Donnell, Arash Rezazadeh Kalebasty, Dingwei Ye, Sanjeev Mariathasan, FabioIa Bene-Tchaleu, Sandrine Bernhard, Chooi Lee, Ian D Davis, Matthew D Galsky
doi : 10.1016/S1470-2045(23)00540-5
Volume 25, Issue 1, January 2024, Pages 29-45
Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study
Aristotelis Bamias, Ian D Davis, Matthew D Galsky, José ? Arranz, Eiji Kikuchi, Enrique Grande, Xavier Garcia del Muro, Se Hoon Park, Ugo De Giorgi, Boris Alekseev, Marina Mencinger, Kouji Izumi, Fabio A Schutz, Javier Puente, Jian-Ri Li, Stefano Panni, Mahmut Gumus, Mustafa ?zgüro?lu, Sanjeev Mariathasan, Yekaterina Poloz, Fabiola Bene-Tchaleu, Chooi Lee, Sandrine Bernhard, Maria De Santis
doi : 10.1016/S1470-2045(23)00539-9
Volume 25, Issue 1, January 2024, Pages 46-61
Treatment-related adverse events, including fatal toxicities, in patients with solid tumours receiving neoadjuvant and adjuvant immune checkpoint blockade: a systematic review and meta-analysis of randomised controlled trials
Yu Fujiwara, Nobuyuki Horita, Elio Adib, Susu Zhou, Amin H Nassar, Zain UL Abideen Asad, Alessio Cortellini, Abdul Rafeh Naqash
doi : 10.1016/S1470-2045(23)00524-7
Volume 25, Issue 1, January 2024, Pages 62-75
Neoadjuvant chemotherapy plus camrelizumab for locally advanced cervical cancer (NACI study): a multicentre, single-arm, phase 2 trial
Kezhen Li*, Jing Chen*, Yingjie Hu*, Yan-Zhou Wang*, Yuanming Shen*, Gang Chen*, Wenju Peng, Zixuan Fang, Bairong Xia, Xiaojun Chen, Kun Song, Yingmei Wang, Dongling Zou, Yan-Chun Wang, Yingyan Han, Xue Feng, Jing Yuan, Shuaiqingying Guo, Xiaolin Meng, Chenzhao Feng, Yin Chen, Jie Yang, Junpeng Fan, Jianliu Wang, Jihui Ai†, Ding Ma†, Chaoyang Sunâ€
doi : 10.1016/S1470-2045(23)00531-4
Volume 25, Issue 1, January 2024, Pages 76-85
Mortality from leading cancers in districts of England from 2002 to 2019: a population-based, spatiotemporal study
Theo Rashid, James E Bennett, David C Muller, Amanda J Cross, Jonathan Pearson-Stuttard, Perviz Asaria, Hima Iyathooray Daby, Daniela Fecht, Bethan Davies, Majid Ezzati
doi : 10.1016/S1470-2045(23)00530-2
Volume 25, Issue 1, January 2024, Pages 86-98
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S Hofman, Louise Emmett, Shahneen Sandhu, Amir Iravani, James P Buteau, Anthony M Joshua, Jeffrey C Goh, David A Pattison, Thean Hsiang Tan, Ian D Kirkwood, Siobhan Ng, Roslyn J Francis, Craig Gedye, Natalie K Rutherford, Andrew Weickhardt, Andrew M Scott, Sze-Ting Lee, Edmond M Kwan, Arun A Azad, Shakher Ramdave, Andrew D Redfern, William Macdonald, Alex Guminski, Edward Hsiao, Wei Chua, Peter Lin, Alison Yan Zhang, Martin R Stockler, Scott G Williams, Andrew J Martin, Ian D Davis, for the TheraP Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group
doi : 10.1016/S1470-2045(23)00529-6
Volume 25, Issue 1, January 2024, Pages 99-107
Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial
Jack Cuzick, Kim Chu, Brian Keevil, Adam R Brentnall, Anthony Howell, Nicholas Zdenkowski, Bernardo Bonanni, Sibylle Loibl, Kaija Holli, D Gareth Evans, Steve Cummings, Mitch Dowsett
doi : 10.1016/S1470-2045(23)00578-8
Volume 25, Issue 1, January 2024, Pages 108-116
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
Yuqin Song*, Luis Malpica*, Qingqing Cai, Weili Zhao, Keshu Zhou, Jianqiu Wu, Huilai Zhang, Neha Mehta-Shah, Kaiyang Ding, Yao Liu, Zengjun Li, Liling Zhang, Meifang Zheng, Jie Jin, Haiyan Yang, Yuerong Shuang, Dok Hyun Yoon, Sujun Gao, Wenyu Li, Zhimin Zhai, Liqun Zou, Yaming Xi, Youngil Koh, Fei Li, Miles Prince, Hui Zhou, Lie Lin, Hui Liu, Pamela Allen, Fernando Roncolato, Zhenfan Yang, Won-Seog Kim*, Jun Zhu
doi : 10.1016/S1470-2045(23)00589-2
Volume 25, Issue 1, January 2024, Pages 117-125
Cumulative incidence of second primary cancers in a large nationwide cohort of Danish cancer survivors: a population-based retrospective cohort study
Trille Kristina Kjaer, Elisabeth Anne Wreford Andersen, Giske Ursin, Signe Benzon Larsen, Pernille Envold Bidstrup, Jeanette Falck Winther, Michael Borre, Christoffer Johansen*, Susanne Oksbjerg Dalton
doi : 10.1016/S1470-2045(23)00538-7
Volume 25, Issue 1, January 2024, Pages 126-136
MRI in addition to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): an international, multicentre, prospective, diagnostic accuracy trial
Burak G?rgec, Ingrid S Hansen, Gunter Kemmerich, Trygve Syversveen, Mohammed Abu Hilal, Eric J T Belt, Koop Bosscha, Mark C Burgmans, Vincent C Cappendijk, Mathieu D’Hondt, Prof Bj?rn Edwin, Arian R van Erkel, Hugo A J Gielkens, Dirk J Grünhagen, Paul D Gobardhan, Henk H Hartgrink, Karin Horsthuis, Elisabeth G Klompenhouwer, Niels F M Kok, Peter A M Kint, Koert Kuhlmann, Wouter K G Leclercq, Daan J Lips, Bart Lutin, Monique Maas, Hendrik A Marsman, Prof Martijn Meijerink, Yannick Meyer, Mario Morone, Jan Peringa, Jasper P Sijberden, Otto M van Delden, Janneke E van den Bergh, Inge J S Vanhooymissen, Maarten Vermaas, François E J A Willemssen, Marcel G W Dijkgraaf, Patrick M Bossuyt, Rutger-Jan Swijnenburg, ?smund A Fretland, Cornelis Verhoef*, Marc G Besselink*, Jaap Stoker*, for the CAMINO Study Group
doi : 10.1016/S1470-2045(23)00572-7
Volume 25, Issue 1, January 2024, Pages 137-146
The future of cancer care in the UK—time for a radical and sustainable National Cancer Plan
Ajay Aggarwal, Ananya Choudhury, Nicola Fearnhead, Pam Kearns, Anna Kirby, Mark Lawler, Sarah Quinlan, Carlo Palmieri, Tom Roques, Richard Simcock, Fiona M Walter, Pat Price*, Richard Sullivan
doi : 10.1016/S1470-2045(23)00511-9
Volume 25, Issue 1, January 2024, Pages e6-e17
Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)
Shankar Siva, Alexander V Louie, Rupesh Kotecha, Melissa N Barber, Muhammad Ali, Zhenwei Zhang, Matthias Guckenberger, Mi-Sook Kim, Marta Scorsetti, Alison C Tree, Ben J Slotman, Arjun Sahgal, Simon S Lo
doi : 10.1016/S1470-2045(23)00513-2
Volume 25, Issue 1, January 2024, Pages e18-e28
PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group
Nathalie L Albert, Norbert Galldiks, Benjamin M Ellingson, Martin J van den Bent, Susan M Chang, Francesco Cicone, John de Groot, Eng-Siew Koh, Ian Law, Emilie Le Rhun, Maximilian J Mair, Giuseppe Minniti, Roberta Rudà , Andrew M Scott, Susan C Short, Marion Smits, Bogdana Suchorska, Nelleke Tolboom, Tatjana Traub-Weidinger, Joerg-Christian Tonn, Antoine Verger, Michael Weller, Patrick Y Wen, Matthias Preusser
doi : 10.1016/S1470-2045(23)00525-9
Volume 25, Issue 1, January 2024, Pages e29-e41
